Volibo M 0.2 Tablet
Metformin + Voglibose
0.25mg
Sun Pharmaceutical Industries Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Indications
Volibo M 0.2 Tablet is used for:
Used in the treatment of type 2 diabetes mellitus.
Adult Dose
Oral
Diabetes mellitus
Adult: 1 tab 1-3 times daily.
Child Dose
Renal Dose
Administration
Should be taken with food.
Contra Indications
Hypersensitivity
Precautions
This medicine should be used with caution in patients with a known history of kidney & liver disease due to the increased risk of worsening of the patient's condition. This medicine is not recommended for use in patients with any gastrointestinal diseases like inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease.
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Metformin + Voglibose :
Flatulence; abdominal distension; nausea, diarrhoea; loss of appetite, stomach pain; skin reactions; hypoglycemia; increased LFT.
Potentially Fatal: Hepatotoxicity.
Mechanism of Action
Voligbose has general properties similar to acarbose and selectively inhibits α-glucosidase in the enteric canal, delaying the digestion and absorption of carbohydrate, thereby suppressing sharp increase in post-prandial plasma glucose.
Metformin is a biguanide w/ antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It decreases hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis; delays intestinal absorption of glucose; and enhances insulin sensitivity by increasing peripheral glucose uptake and utilisation.
Note
Volibo M 0.2 0.25mg Tablet manufactured by Sun Pharmaceutical Industries Ltd.. Its generic name is Metformin + Voglibose. Volibo M 0.2 is availble in Nepal.
Farmaco Nepal drug index information on Volibo M 0.2 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.